Skip to main content

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

Publication ,  Conference
Catenacci, DVT; Park, H; Lockhart, AC; Gold, PJ; Enzinger, PC; Nordstrom, JL; Hong, S; Hochster, HS; Kelly, RJ; Uronis, HE; Bendell, JC ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 1, 2018

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 1, 2018

Volume

36

Issue

4

Location

San Francisco, CA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Gastrointestinal Cancers Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Catenacci, D. V. T., Park, H., Lockhart, A. C., Gold, P. J., Enzinger, P. C., Nordstrom, J. L., … Bang, Y.-J. (2018). Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 36). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
Catenacci, Daniel V. T., Haeseong Park, A Craig Lockhart, Philip Jordan Gold, Peter C. Enzinger, Jeffrey L. Nordstrom, Sam Hong, et al. “Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
Catenacci DVT, Park H, Lockhart AC, Gold PJ, Enzinger PC, Nordstrom JL, et al. Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2018.
Catenacci, Daniel V. T., et al. “Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 4, AMER SOC CLINICAL ONCOLOGY, 2018.
Catenacci DVT, Park H, Lockhart AC, Gold PJ, Enzinger PC, Nordstrom JL, Hong S, Hochster HS, Kelly RJ, Uronis HE, Bendell JC, Oh SC, Park SH, Kim YH, Kang Y-K, Lee K-W, Ng MCH, Wigginton JM, Davidson-Moncada JK, Bang Y-J. Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2018.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 1, 2018

Volume

36

Issue

4

Location

San Francisco, CA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Gastrointestinal Cancers Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences